The Aporia
Musto, J. (2026, November 9). US is requiring weight-loss drug makers to warn about possible loss of eye sight. The Independent. https://www.independent.co.uk/news/health/glp1-weight-loss-drug-vision-loss-b3081915.html
Musto, Julia. “US is requiring weight-loss drug makers to warn about possible loss of eye sight.” The Independent, 9 Nov. 2026, https://www.independent.co.uk/news/health/glp1-weight-loss-drug-vision-loss-b3081915.html.
Musto, Julia. “US is requiring weight-loss drug makers to warn about possible loss of eye sight.” The Independent, November 9, 2026. https://www.independent.co.uk/news/health/glp1-weight-loss-drug-vision-loss-b3081915.html.
Dated from the outlet's own feed. Check the original for its byline.
The U.S. Food and Drug Administration (FDA) announced on November 6, 2026, that manufacturers of popular weight-loss drugs like Ozempic and Zepbound must warn about an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to permanent vision loss. According to a July Gallup poll, approximately 28 million Americans are currently using these GLP-1 drugs for weight management. This update highlights the importance of alerting patients and healthcare providers about potential side effects associated with long-term use of these medications.